Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Dr. Biao Xi, Principle Scientist at ACEA Biosciences receives the 2014 JALA Authors Choice Award for His Study on Preclinical Cardiac Safety Assessment
  • USA - English


News provided by

ACEA Biosciences, Inc.

Feb 24, 2014, 13:10 ET

Share this article

Share toX

Share this article

Share toX


"...we have seen quick adoption of our technology in the assessment of preclinical cardiac safety in pharmaceutical industry, academic institutions, CRO companies and governmental agencies..", said said Dr. Yama Abassi, Vice President of ACEA Biosciences

Post this

San Diego, CA (PRWEB) February 24, 2014 -- Announced at the Society for Laboratory Automation and Screening Conference and Exhibition in San Diego January 18-22, 2014, Dr. Biao Xi was awarded the 2014 JALA Authors Choice Award for his publication entitled “Functional Cardiotoxicity Profiling and Screening Using the xCELLigence RTCA-Cardio System”. This prestigious award recognizes the manuscript’s popularity among life science authors (citations) throughout 2013. This article, published in JALA (December 2011, Volume 16, Issue 6, Pages 415-421), was co-authored by Tianxing Wang, Nan Li, Wei Ouyang, William Zhang, Jieying Wu, Xiao Xu, Xiaobo Wang and Yama A. Abassi. To honor Journal Achievement Awards, the Journal of Laboratory Automation (JALA) now provides open-access to this article at JALA Online (jla.sagepub.com).

Cardiac liability continues to be a major topic of concern in drug development. Between 1990 and 2006, one third of all safety-related drug withdrawals were attributed to cardiotoxicity. Driven by the pharmaceutical industry, there has been a significant need to develop higher throughput and more predictive assays that can be used earlier in drug development to minimize both cost and risk. The xCELLigence RTCA-Cardio System (launched in 2010) is an impedance-based microelectronic detection system that monitors the beating function of cardiomyocytes in a 96-well format. The study led by Xi, et al validated the xCELLigence System by applying a variety of tool compounds and drugs with known mechanisms of action to mouse embryonic stem cell-derived cardiomyocytes, human-induced pluripotent stem cell-derived cardiomyocytes, and rat neonatal primary cardiomyocytes. The results demonstrate that the RTCA-Cardio System is able to sensitively and quantitatively detect the effect of ion channel and nonion channel modulators of cardiac function in real time. Furthermore, pro-arrhythmic compounds produce a characteristic beating profile, which may be reflective of the risk of arrhythmia. In addition, the ability to use the time resolution in the assay in conjunction with the physical beating of cardiomyocytes, the effect of certain compounds missed by electrophysiological readouts can be detected.

"We are excited to learn that Dr. Xi was elected for JALA Authors Choice Award this year,” said Dr. Yama Abassi, Vice President of ACEA Biosciences. "Since our 2011 JALA publication, we have seen quick adoption of our technology in the assessment of preclinical cardiac safety in pharmaceutical industry, academic institutions, CRO companies and governmental agencies. Specifically, the Safety Tox group at Roche established and published in Toxicol. Sci (2011; 123 (1): 281-289) a new metric, Predicted Proarrhythmic Score (PPS), which demonstrates an improvement in accuracy of predicting cardiac arrhythmias compared to hERG screening and QT prolongation studies. In addition, they believe that the RTCA-Cardio will not only help them in early discovery safety assessment, but open up new opportunities for investigating, cardiac biology, cell signaling and disease pathogenesis.”

Yama further commented, “With the recent focus of the US FDA to modify preclinical regulatory guidelines for assessment of cardiovascular risk and by focusing on arrhythmia, rather than QT prolongation, the xCELLigence RTCA-Cardio System is poised to play a significant role in Preclinical Cardiac Safety Assessment.”

###

About the xCELLigence RTCA-Cardio System
The xCELLigence RTCA-Cardio System dynamically monitors cardiomyocyte beating and cellular events by impedance readings in a 96-well format. It records electrical impedance of cells grown on gold microelectrode arrays integrated into the bottom of each well of an E-Plate Cardio 96. In contrast to single-cell, acute techniques like patch clamp, the xCELLigence System provides real-time, label-free beating pattern analysis and is used in a fully controlled environment (within a tissue culture incubator) for continuous short-term and long-term experiments, allowing for more physiologically relevant data. The xCELLigence RTCA-Cardio System in combination with human iPSC-derived cardiomyocytes has shown great promise as a highly predictive in vitro assay for assessment of drug induced cardiac liability. In 2013 alone, seven studies using cardiomyocytes with this system have been published. The results collectively showed that the xCELLigence RTCA-Cardio system addresses unmet needs of in vitro cardio safety screening by:
• Being a high-throughput method for detecting functional cardiotoxicity (effects on short-term and long-term cardio beating activity) and general toxicity in vitro
• Having good correlation with clinical arrhythmogenic risk
• Providing insight to compound mechanism of action

About ACEA Biosciences
Founded in 2002, ACEA Biosciences, Inc. (ACEA) is a privately held biotechnology company pioneering in the development and commercialization of high-performance microelectronic systems for cell-based assays. With headquarters in San Diego, CA, ACEA has developed proprietary real-time, label-free cell-based assay technology and launched its first product in 2004. Today, the company has a product line of 6 instruments which utilize this technology with different functionalities and throughputs. They enable different types of cellular-based assay applications. ACEA continuously developing new technology. The systems are commercialized globally under the xCELLigence® brand with over 1,000 instrument placements worldwide and over 500 peer-reviewed publications. This technology is being utilized in academic labs, government institutions, biotech and pharma companies across the world in diverse fields such as cancer, regenerative medicine, inflammation, infectious diseases, and toxicity research. For more information, http://www.aceabio.com.

For further information please contact:
ACEA Biosciences, Inc.
Dr. Leyna Zhao
Phone: +1 858 724 0928 x 3066
email: lzhao(at)aceabio(dot)com

Amy de Leon, ACEA Biosciences, Inc., http://www.aceabio.com, +1 8587240928 Ext: 3090, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.